CR8087A - DERIVADOS DE BENCIMIDAZOL COMO INHIBIDORES DEL FACTOR Xa - Google Patents
DERIVADOS DE BENCIMIDAZOL COMO INHIBIDORES DEL FACTOR XaInfo
- Publication number
- CR8087A CR8087A CR8087A CR8087A CR8087A CR 8087 A CR8087 A CR 8087A CR 8087 A CR8087 A CR 8087A CR 8087 A CR8087 A CR 8087A CR 8087 A CR8087 A CR 8087A
- Authority
- CR
- Costa Rica
- Prior art keywords
- factor
- compounds
- inhibitors
- situations
- formula
- Prior art date
Links
- 108010074860 Factor Xa Proteins 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 108010054265 Factor VIIa Proteins 0.000 abstract 4
- 229940012414 factor viia Drugs 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente invencion se refiere a compuestos de la formula (I) en la que R0,R1,R2,Q,V,G y M tiene los significados indicados en las reivindicaciones. Los compuestos de la formula (I) son compuestos farmacologicamente activos valiosos. Muestran un fuerte efecto antitrombotico y son adecuados, por ejemplo, para la terapia y profilaxis de trastornos cardiovasculares tales como enfermedades tromboembolicas o reestenosis. Son inhibidores reversibles de las enzimas de la coagulacion sanguinea factor Xa (FXa) y/o factor VIIa (FVIIa) y en general pueden aplicarse en situaciones en las que esta presente una actividad indeseada del factor Xa y/o del factor VIIa o en situaciones para cuya duracion o prevencion se desea la inhibicion del factor Xa y/o del factor VIIa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03011305A EP1479676A1 (en) | 2003-05-19 | 2003-05-19 | Benzimidazole-derivatives as factor xa inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR8087A true CR8087A (es) | 2006-09-22 |
Family
ID=33040952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR8087A CR8087A (es) | 2003-05-19 | 2005-11-11 | DERIVADOS DE BENCIMIDAZOL COMO INHIBIDORES DEL FACTOR Xa |
Country Status (29)
| Country | Link |
|---|---|
| EP (2) | EP1479676A1 (es) |
| JP (1) | JP4658940B2 (es) |
| KR (1) | KR20060014056A (es) |
| CN (2) | CN101139346A (es) |
| AR (1) | AR045683A1 (es) |
| AT (1) | ATE474838T1 (es) |
| AU (1) | AU2004238497B2 (es) |
| BR (1) | BRPI0410446A (es) |
| CA (1) | CA2526065A1 (es) |
| CL (1) | CL2004001078A1 (es) |
| CR (1) | CR8087A (es) |
| DE (1) | DE602004028240D1 (es) |
| EC (1) | ECSP056178A (es) |
| MA (1) | MA27798A1 (es) |
| MX (1) | MXPA05012231A (es) |
| NO (1) | NO20055910L (es) |
| NZ (1) | NZ543670A (es) |
| OA (1) | OA13168A (es) |
| PA (1) | PA8603501A1 (es) |
| PE (1) | PE20050198A1 (es) |
| RS (1) | RS20050856A (es) |
| RU (1) | RU2346944C2 (es) |
| SA (1) | SA04250196B1 (es) |
| TN (1) | TNSN05297A1 (es) |
| TW (1) | TW200503696A (es) |
| UA (1) | UA82100C2 (es) |
| UY (1) | UY28324A1 (es) |
| WO (1) | WO2004101553A1 (es) |
| ZA (1) | ZA200508151B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10342570A1 (de) | 2003-09-15 | 2005-04-14 | Bayer Healthcare Ag | Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon |
| AU2005324492B2 (en) | 2004-04-23 | 2012-06-07 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| WO2008033739A2 (en) * | 2006-09-12 | 2008-03-20 | Neurogen Corporation | Benzimidazole carboxamide derivatives |
| DE102010018299A1 (de) | 2010-04-23 | 2011-10-27 | Archimica Gmbh | Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on |
| CN105829293B (zh) * | 2013-12-20 | 2018-11-09 | 中国人民解放军军事医学科学院毒物药物研究所 | 新型哌啶氨甲酰类化合物、制备方法及其用途 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1377642A (en) * | 1971-01-14 | 1974-12-18 | Koninklijke Gist Spiritus | Penicillanic and cephalosporanic acid derivatives |
| US4269846A (en) * | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
| JPH0784462B2 (ja) * | 1986-07-25 | 1995-09-13 | 日清製粉株式会社 | ベンゾイミダゾ−ル誘導体 |
| US4897401A (en) * | 1987-06-19 | 1990-01-30 | Janssen Pharmaceutical N.V. | N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives useful in treating allergic diseases |
| DE3828537A1 (de) * | 1988-08-23 | 1990-03-01 | Basf Ag | Neue n-substituierte benzimidazol-2-carbonsaeureanilide, deren verwendung als lichtschutzmittel, insbesondere polymere und diese anilide enthaltendes organisches material |
| JPH0324609A (ja) * | 1989-06-21 | 1991-02-01 | Mitsuba Electric Mfg Co Ltd | Ｉ／ｏ用バッファｉｃ |
| JPH03184043A (ja) * | 1989-12-14 | 1991-08-12 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| KR100190299B1 (ko) * | 1990-07-19 | 1999-06-01 | 디르크 반테 | 신규한 옥사졸릴 유도체 |
| DE4304650A1 (de) * | 1993-02-16 | 1994-08-18 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE69524241T2 (de) * | 1994-09-30 | 2002-06-13 | Pfizer Inc., New York | 2,7,-substituierte octahydro-1h-pyrido[1,2-a]pyrazin derivate |
| JPH08208640A (ja) * | 1995-02-06 | 1996-08-13 | Nisshin Flour Milling Co Ltd | ベンズイミダゾール誘導体およびそれを含有する心不全治療薬 |
| JPH08295667A (ja) * | 1995-04-27 | 1996-11-12 | Takeda Chem Ind Ltd | 複素環化合物、その製造法および剤 |
| JPH09124609A (ja) * | 1995-11-07 | 1997-05-13 | Nissan Chem Ind Ltd | ベンズイミダゾール誘導体 |
| JPH10182459A (ja) * | 1996-12-26 | 1998-07-07 | Otsuka Pharmaceut Co Ltd | ｃＧＭＰ分解酵素阻害剤 |
| UA62972C2 (en) * | 1997-07-03 | 2004-01-15 | Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders | |
| SK15072000A3 (sk) * | 1998-04-10 | 2001-08-06 | Japan Tobacco Inc. | Amidové zlúčeniny |
| PL377087A1 (pl) * | 2002-09-06 | 2006-01-23 | Janssen Pharmaceutica, N.V. | Związki heterocykliczne |
-
2003
- 2003-05-19 EP EP03011305A patent/EP1479676A1/en not_active Withdrawn
-
2004
- 2004-05-03 PE PE2004000446A patent/PE20050198A1/es not_active Application Discontinuation
- 2004-05-05 WO PCT/EP2004/004750 patent/WO2004101553A1/en not_active Ceased
- 2004-05-05 CN CNA2007101491602A patent/CN101139346A/zh active Pending
- 2004-05-05 RU RU2005139555/04A patent/RU2346944C2/ru not_active IP Right Cessation
- 2004-05-05 KR KR1020057022122A patent/KR20060014056A/ko not_active Ceased
- 2004-05-05 CN CNB2004800139377A patent/CN100484935C/zh not_active Expired - Fee Related
- 2004-05-05 BR BRPI0410446-3A patent/BRPI0410446A/pt not_active IP Right Cessation
- 2004-05-05 MX MXPA05012231A patent/MXPA05012231A/es active IP Right Grant
- 2004-05-05 EP EP04731162A patent/EP1636216B1/en not_active Expired - Lifetime
- 2004-05-05 NZ NZ543670A patent/NZ543670A/en unknown
- 2004-05-05 AU AU2004238497A patent/AU2004238497B2/en not_active Expired - Fee Related
- 2004-05-05 RS YUP-2005/0856A patent/RS20050856A/sr unknown
- 2004-05-05 UA UAA200512138A patent/UA82100C2/uk unknown
- 2004-05-05 JP JP2006529739A patent/JP4658940B2/ja not_active Expired - Fee Related
- 2004-05-05 CA CA002526065A patent/CA2526065A1/en not_active Abandoned
- 2004-05-05 AT AT04731162T patent/ATE474838T1/de not_active IP Right Cessation
- 2004-05-05 OA OA1200500322A patent/OA13168A/en unknown
- 2004-05-05 DE DE602004028240T patent/DE602004028240D1/de not_active Expired - Lifetime
- 2004-05-17 AR ARP040101695A patent/AR045683A1/es not_active Application Discontinuation
- 2004-05-17 TW TW093113795A patent/TW200503696A/zh unknown
- 2004-05-17 CL CL200401078A patent/CL2004001078A1/es unknown
- 2004-05-19 PA PA20048603501A patent/PA8603501A1/es unknown
- 2004-05-19 UY UY28324A patent/UY28324A1/es unknown
- 2004-06-30 SA SA04250196A patent/SA04250196B1/ar unknown
-
2005
- 2005-10-10 ZA ZA200508151A patent/ZA200508151B/xx unknown
- 2005-11-08 MA MA28587A patent/MA27798A1/fr unknown
- 2005-11-11 CR CR8087A patent/CR8087A/es not_active Application Discontinuation
- 2005-11-18 TN TNP2005000297A patent/TNSN05297A1/en unknown
- 2005-11-18 EC EC2005006178A patent/ECSP056178A/es unknown
- 2005-12-13 NO NO20055910A patent/NO20055910L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP045115A (es) | INDOL-2-CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa | |
| UY28778A1 (es) | Derivados de pirrol como inhibidores del factor xa | |
| UY28325A1 (es) | Nuevos derivados de indol como inhibidores del factor xa | |
| EA201001523A1 (ru) | Ингибиторы матриксной металлопротеазы на основе арилсульфонамида | |
| TW200510400A (en) | Indazole-derivatives as factor Xa inhibitors | |
| MX2025010920A (es) | Compuestos quimicos | |
| TW200505914A (en) | Pyrazole-derivatives as factor Xa inhibitors | |
| EA200800006A1 (ru) | Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i | |
| HN2001000019A (es) | Derivados de nicotinamida benzocondensada heterociclico utiles como inhibidores selectivos de las isozimas pde4. | |
| NO20084502L (no) | Tetrahydropyrrolopyrimidinedioner og deres anvendelse som humane neutrofil elastase inhibitorer | |
| BRPI0412999A (pt) | 2-aminotetralina substituìda para tratamento de depressão | |
| NO20063676L (no) | Indolderivater og anvendelse derav som kinaseinhibitorer i spesielle IKK2 inhibitorer | |
| ATE331711T1 (de) | Entzündungshemmende 3-arylthio-3- thiazolylalkylamine | |
| CR8087A (es) | DERIVADOS DE BENCIMIDAZOL COMO INHIBIDORES DEL FACTOR Xa | |
| PA8816101A1 (es) | Clorotiofeno - amidas como inhibidores de los factores de coagulacion xa y trombina | |
| NO20043792L (no) | New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine | |
| GT200500026A (es) | Derivados de beta-aminoacidos como inhibidores del factor xa. | |
| AR026257A1 (es) | N-guanidinoalquilamidas, su preparacion, su uso y composiciones farmaceuticas que las contienen | |
| CR8088A (es) | DERIVADOS DE AZAINDOL COMO INHIBIDORES DEL FACTOR Xa | |
| PE20050154A1 (es) | DERIVADOS DE TRIAZOL COMO INHIBIDORES DEL FACTOR Xa | |
| ATE394414T1 (de) | Hemmstoffe des gerinnungsfaktors xa, ihre herstellung und verwendung | |
| EP4119165A4 (en) | NOVEL 3,5-DIAMINOBENZOIC ACID COMPOUND, AND PIN1 INHIBITOR AND THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES USING SAME | |
| NO20061821L (no) | Amidometylsubstituerte 1-(karboksyalkyl)-syklopentylkarbonylaminobenzazepin-N-eddiksyrederivater, fremgangsmate og mellomprodukter for deres fremstilling, og medikamenter som inneholder disse forbindelsene | |
| UY28993A1 (es) | Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm, procedimiento para su uso como medicamento.- | |
| SV2003001524A (es) | Nuevos derivados de indol como inhibidores del factor xa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |